ctDNA Testing in Colorectal Cancer Deemed Promising but Not Ready for Prime Time
Studies suggest that ctDNA testing has prognostic value in colorectal cancer, but more research is needed before it can be used in practice.
Diagnosis & Disease Information
Nonsurgical Approach Deemed Feasible for Patients With Early Rectal Cancer
A nonsurgical treatment strategy employing chemoradiotherapy is feasible for patients with early rectal cancer, a phase 3 trial suggests.
Adding Nab-Paclitaxel to Standard Care Does Not Improve Outcomes in Biliary Tract Cancers
Adding nab-paclitaxel to gemcitabine and cisplatin does not improve outcomes in newly diagnosed, advanced biliary tract cancers, a phase 3 trial suggests.
Trifluridine Plus Tipiracil and Bevacizumab Deemed New Standard Care for Refractory Metastatic Colorectal Cancer
Adding bevacizumab to treatment with trifluridine and tipiracil improved outcomes in patients with refractory metastatic colorectal cancer in the phase 3 SUNLIGHT trial.
Benefit Seen With SBRT Before Sorafenib in Advanced HCC
SBRT prior to sorafenib improved outcomes, compared with sorafenib alone, in a phase 3 trial of patients with advanced hepatocellular carcinoma.
ctDNA Monitoring Shows Promise for Anal Cancer Patients Receiving Chemoradiation
Monitoring of ctDNA may be useful for early response assessment in patients with anal cancer receiving chemoradiation, a study suggests.
Botensilimab Plus Balstilimab Yields Durable Responses in Refractory Metastatic Colorectal Cancer
Combination botensilimab and balstilimab elicits durable responses in refractory, metastatic, microsatellite-stable colorectal cancer, a phase 1 trial suggests.
NAPOLI-3 Results Support NALIRIFOX for Metastatic Pancreatic Cancer
NALIRIFOX outperformed treatment with nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer in the NAPOLI-3 trial.
Nanvuranlat Improves PFS in Heavily Pretreated, Advanced Biliary Tract Cancer
Nanvuranlat improved progression-free survival, compared with placebo, in heavily pretreated patients with advanced biliary tract cancer.
Combining TACE and Sorafenib Improves Survival in HCC With PVTT
The addition of transarterial chemoembolization to adjuvant sorafenib improved outcomes for patients with hepatocellular carcinoma and portal vein tumor thrombosis in a phase 2 trial.
- Loading...
Loading...
Next post in ASCO GI 2023
Loading... 
Loading...